NCT03239340 | AstraZeneca|Parexel | EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | May 30, 2018 | Phase 2 |
NCT05629234 | AstraZeneca|Parexel | Cancer | May 8, 2023 | Phase 3 |
NCT03394118 | Asan Medical Center|AstraZeneca | NSCLC | August 11, 2017 | Phase 2 |
NCT05816252 | Klus Pharma Inc.|Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | April 19, 2023 | Phase 2 |
NCT05281406 | Goethe University | NSCLC Stage IIIB|NSCLC Stage IV | November 12, 2021 | Phase 2 |
NCT04438902 | First Affiliated Hospital of Zhejiang University | Non Small Cell Lung Cancer | December 12, 2020 | Phase 2 |
NCT05773092 | National Cancer Centre, Singapore|Taiho Pharmaceutical Co., Ltd. | NSCLC | March 27, 2023 | Phase 2 |
NCT05513664 | Shanghai JMT-Bio Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer|EGFR Exon20 Insertion Mutations | September 2022 | |
NCT05132777 | Shanghai JMT-Bio Inc.|CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer|EGFR Exon20 Insertion Mutations | November 20, 2021 | Phase 2 |
NCT04001777 | Ascentage Pharma Group Inc.|Suzhou Yasheng Pharmaceutical Co., Ltd. | EGFR Positive Non-small Cell Lung Cancer | July 4, 2019 | Phase 1 |
NCT05546866 | AstraZeneca | Non-small Cell Lung Cancer | February 21, 2023 | Phase 2 |
NCT02856893 | European Organisation for Research and Treatment of Cancer - EORTC|AstraZeneca | NSCLC | October 10, 2017 | Phase 2 |
NCT03667820 | University of Texas Southwestern Medical Center|AstraZeneca | Non-small Cell Lung Cancer (NSCLC) | September 26, 2018 | Phase 2 |
NCT05382728 | TYK Medicines, Inc | NSCLC|EGFR Activating Mutation | June 8, 2022 | Phase 3 |
NCT04606771 | AstraZeneca | Non-Small Cell Lung Cancer | September 28, 2020 | Phase 2 |
NCT04181060 | National Cancer Institute (NCI) | Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Recurrent Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8 | October 22, 2020 | Phase 3 |
NCT04959981 | Erasca, Inc. | Advanced Non-squamous Non-small-cell Lung Cancer | September 2, 2021 | Phase 1 |
NCT01802632 | AstraZeneca | Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer | March 4, 2013 | Phase 1|Phase 2 |
NCT04816214 | Novartis Pharmaceuticals|Novartis | Carcinoma, Non-Small-Cell Lung | September 22, 2021 | Phase 3 |
NCT04720976 | Jacobio Pharmaceuticals Co., Ltd.|AbbVie | Solid Tumor|NSCLC | March 23, 2021 | Phase 1|Phase 2 |
NCT02163733 | AstraZeneca | Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer | November 14, 2014 | Phase 1 |
NCT03414814 | Seoul National University Hospital|AstraZeneca|Korean Cancer Study Group | Locally Advanced or Metastatic NSCLC | January 4, 2018 | Phase 2 |
NCT02496663 | National Cancer Institute (NCI) | Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8 | May 11, 2016 | Phase 1 |
NCT04575415 | Guangdong Association of Clinical Trials | NSCLC | October 7, 2020 | |
NCT03732352 | Jonsson Comprehensive Cancer Center|AstraZeneca | EGFR Gene Amplification|EGFR Gene Mutation|Glioblastoma|Recurrent Glioblastoma|Supratentorial Glioblastoma|TP53 wt Allele | November 28, 2018 | Phase 2 |
NCT03535363 | Case Comprehensive Cancer Center | NSCLC|Non-small Cell Lung Cancer | October 26, 2018 | Phase 1 |
NCT03833154 | AstraZeneca | Carcinoma, Non-Small-Cell Lung | March 6, 2019 | Phase 3 |
NCT04908956 | ETOP IBCSG Partners Foundation|AstraZeneca | NSCLC Stage IV|EGFR Gene Mutation | August 4, 2022 | Phase 2 |
NCT02954523 | Chul Kim|AstraZeneca|Bristol-Myers Squibb|Walter Reed National Military Medical Center|Hackensack Meridian Health|Georgetown University | EGFR Gene Mutation|Nonsmall Cell Lung Cancer | October 2016 | Phase 1|Phase 2 |
NCT03040973 | Novartis Pharmaceuticals|Novartis | Advanced Solid Tumors Which Are cMET-dependent | July 4, 2017 | Phase 2 |
NCT02454933 | AstraZeneca | Locally Advanced or Metastatic EGFR T790M&addition; NSCLC | July 15, 2015 | Phase 3 |
NCT05583409 | Li Zhang|Hubei Cancer Hospital|Tongji Hospital | Stage IV Non-small Cell Lung Cancer | January 1, 2023 | Not Applicable |
NCT05880706 | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | July 2023 | Phase 2 |
NCT03831932 | National Cancer Institute (NCI) | Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8 | March 16, 2020 | Phase 1|Phase 2 |
NCT02096679 | AstraZeneca | Healthy Volunteers | May 2014 | Phase 1 |
NCT02317016 | AstraZeneca | Non Small Cell Lung Cancer | March 10, 2015 | Phase 1 |
NCT02917993 | Incyte Corporation|AstraZeneca | Lung Cancer | December 20, 2016 | Phase 1|Phase 2 |
NCT04563871 | Samsung Medical Center|AstraZeneca | Non-small Cell Lung Cancer (NSCLC) | November 17, 2020 | Phase 2 |
NCT02972333 | Shandong Cancer Hospital and Institute|AstraZeneca | EGFR-TKI Resistant Mutation|Nonsmall Cell Lung Cancer|AZD9291|Brain Metastases | December 2016 | Phase 3 |
NCT05104281 | Qingdao Central Hospital | Carcinoma, Non-Small-Cell Lung | January 1, 2021 | Phase 3 |
NCT05120960 | M.D. Anderson Cancer Center | Brain Tumor | February 27, 2023 | Phase 1 |
NCT02529995 | AstraZeneca | Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive | August 24, 2015 | Phase 1 |
NCT03909334 | Xiuning Le|M.D. Anderson Cancer Center|Eli Lilly and Company|Hoosier Cancer Research Network | Non Small Cell Lung Cancer|EGFR Gene Mutation|Advanced Cancer|Metastatic Cancer | July 25, 2019 | Phase 2 |
NCT05085054 | Wuhan Union Hospital, China | Non Small Cell Lung Cancer | June 1, 2022 | Phase 2 |
NCT03810066 | University Hospital, Essen | NSCLC|EGFR T790M|FDG-PET | June 3, 2019 | Phase 2 |
NCT02811354 | National University Hospital, Singapore|AstraZeneca|Singapore Clinical Research Institute | Carcinoma, Non-Small-Cell Lung | February 24, 2017 | Phase 2 |
NCT05103605 | AstraZeneca | Non Small Cell Lung Cancer | May 12, 2021 | |
NCT05954871 | Genentech, Inc. | Colorectal Cancer|Non-Small Cell Lung Cancer | August 31, 2023 | Phase 1 |
NCT05834348 | Pfizer | Non-Small Cell Lung Cancer | May 1, 2023 | |
NCT04770688 | Shanghai Chest Hospital | Non-Small Cell Lung Cancer With EGFR Mutation|Locally Advanced Solid Tumor|Metastatic Cancer|Adenocarcinoma of Lung | November 19, 2020 | Phase 1|Phase 2 |
NCT02503722 | National Cancer Institute (NCI) | Metastatic Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 | October 13, 2016 | Phase 1 |
NCT03567642 | Memorial Sloan Kettering Cancer Center | Lung Cancer | June 12, 2018 | Phase 1 |
NCT05785208 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Non Small Cell Lung Cancer | June 28, 2022 | Phase 4 |
NCT04351555 | AstraZeneca | Non-Small Cell Lung Cancer | December 16, 2020 | Phase 3 |
NCT05498389 | Shanghai EpimAb Biotherapeutics Co., Ltd.|Labcorp Corporation of America Holdings, Inc | Metastatic Lung Non-Small Cell Carcinoma|Advanced Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|EGFR Mutation-Related Tumors | June 2023 | Phase 1|Phase 2 |
NCT03944772 | AstraZeneca | Non-Small Cell Lung Cancer | June 25, 2019 | Phase 2 |
NCT04591002 | Samsung Medical Center | Lung Cancer | October 7, 2020 | Phase 2 |
NCT04541407 | University of Colorado, Denver|Cancer League of Colorado | Non Small Cell Lung Cancer|CNS Progression | October 29, 2020 | Phase 1 |
NCT03455829 | G1 Therapeutics, Inc. | Carcinoma, Non-Small-Cell Lung|Lung Cancer|Non-small Cell Lung Cancer | March 29, 2018 | Phase 1|Phase 2 |
NCT03865511 | Nantes University Hospital|AstraZeneca | Non-small Cell Lung Cancer | April 9, 2019 | Phase 2 |
NCT03122717 | Dana-Farber Cancer Institute|AstraZeneca | Non-Small Cell Lung Cancer | May 9, 2017 | Phase 1|Phase 2 |
NCT05647122 | AstraZeneca | Advanced Solid Tumours|Carcinoma Non-small Cell Lung|Head and Neck Neoplasms | December 22, 2022 | Phase 1 |
NCT02157883 | AstraZeneca | Advanced Non Small Cell Lung Cancer|Advanced (Inoperable) Non Small Cell Lung Cancer | November 6, 2014 | Phase 1 |
NCT03133546 | ETOP IBCSG Partners Foundation|AstraZeneca|Hoffmann-La Roche | Non Small Cell Lung Cancer Metastatic | May 31, 2017 | Phase 2 |
NCT04816838 | Yonsei University | Non Small Cell Lung Cancer | May 10, 2021 | Not Applicable |
NCT03989115 | Revolution Medicines, Inc.|Sanofi | Solid Tumor | July 2, 2019 | Phase 1|Phase 2 |
NCT04974879 | Qingdao Central Hospital | Carcinoma, Non-Small-Cell Lung | July 1, 2021 | Phase 2 |
NCT02504346 | Oslo University Hospital|AstraZeneca | Lung Cancer|Targeted Therapy | August 2015 | Phase 2 |
NCT02841579 | MedSIR|AstraZeneca | Non-Small Cell Lung Cancer | August 2016 | Phase 2 |
NCT02179671 | AstraZeneca|Quintiles, Inc. | Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) | July 25, 2014 | Phase 2 |
NCT03191149 | National Cancer Institute (NCI) | Advanced Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 | April 5, 2018 | Phase 2 |
NCT02099058 | AbbVie | Advanced Solid Tumors Cancer | January 15, 2014 | Phase 1 |
NCT04233021 | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic|Leptomeningeal Metastasis|Brain Metastases|EGFR Activating Mutation | July 16, 2020 | Phase 2 |
NCT04184921 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Lung Cancer Non-small Cell Stage IV | August 1, 2020 | |
NCT04870190 | Shanghai Chest Hospital | NSCLC | June 1, 2021 | Phase 3 |
NCT04141644 | University of Utah | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) | August 20, 2020 | Phase 1 |
NCT05507606 | Tianjin Medical University Cancer Institute and Hospital | Non Small Cell Lung Cancer | August 1, 2021 | Phase 2 |
NCT02411448 | Eli Lilly and Company | Metastatic Non-Small Cell Lung Cancer | May 6, 2015 | Phase 3 |
NCT04391283 | First Affiliated Hospital of Zhejiang University|AstraZeneca | Carcinoma, Non-Small-Cell Lung | July 27, 2020 | |
NCT03532698 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-Small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|EGFR T790M | August 1, 2020 | |
NCT04695925 | Li Zhang, MD|Sun Yat-sen University | Non-small Cell Carcinoma|EGFR Gene Mutation | January 4, 2021 | Phase 3 |
NCT02959749 | Qingdao Central Hospital | Progression Free Survival | August 2015 | Phase 2|Phase 3 |
NCT02789345 | Eli Lilly and Company|AstraZeneca | Non-small Cell Lung Cancer | October 24, 2016 | Phase 1 |
NCT04743505 | Washington University School of Medicine|Apollomics Inc. | Metastatic Non Small Cell Lung Cancer | January 18, 2022 | Phase 1|Phase 2 |
NCT03424759 | Samsung Medical Center | Non Small Cell Lung Cancer | January 1, 2016 | Phase 2 |
NCT05015608 | Hutchison Medipharma Limited|Hutchmed | Non-small Cell Lung Cancer | November 22, 2021 | Phase 3 |
NCT05166616 | City of Hope Medical Center|National Cancer Institute (NCI) | Advanced Lung Non-Small Cell Carcinoma|Locally Advanced Lung Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Unresectable Lung Non-Small Cell Carcinoma | March 7, 2022 | Phase 1 |
NCT02971501 | National Cancer Institute (NCI) | Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Neoplasm in the Brain|Stage IV Lung Cancer AJCC v8 | June 27, 2018 | Phase 2 |
NCT02094261 | AstraZeneca | Non Small Cell Lung Cancer | May 20, 2014 | Phase 2 |
NCT05120349 | AstraZeneca | Non-Small Cell Lung Cancer | February 21, 2022 | Phase 3 |
NCT03460275 | Sun Yat-sen University | Non-small Cell Lung Cancer | February 26, 2018 | Phase 2 |
NCT04413201 | Michael Hopp|Boehringer Ingelheim|Johannes Gutenberg University Mainz | Non-squamous NSCLC | September 11, 2020 | Phase 4 |
NCT04479306 | M.D. Anderson Cancer Center | Recurrent Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 | June 18, 2020 | Phase 1 |
NCT03810807 | Memorial Sloan Kettering Cancer Center | Metastatic Non-small Cell Lung Cancer | January 17, 2019 | Phase 1 |
NCT04829019 | Sun Yat-sen University | Neurocognitive | April 7, 2021 | Phase 2 |
NCT04546282 | University Hospital, Montpellier | Non Small Cell Lung Cancer | July 1, 2017 | |
NCT02197234 | AstraZeneca | Non Small Cell Lung Cancer | December 22, 2014 | Phase 1 |
NCT03133234 | AstraZeneca | T790M Positive NSCLC Patients | May 23, 2017 | |
NCT04676477 | Daiichi Sankyo, Inc. | Non-Small Cell Lung Cancer (NSCLC) | June 11, 2021 | Phase 1 |
NCT02296125 | AstraZeneca|Parexel | Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer | December 3, 2014 | Phase 3 |
NCT04988607 | Guangdong Association of Clinical Trials | Lung Cancer | August 2021 | Phase 2 |
NCT03418532 | Molecular Partners AG | EGFR-mutated NSCLC (Disorder) | March 22, 2018 | Phase 1 |
NCT03370770 | Boehringer Ingelheim | Carcinoma, Non-Small-Cell Lung | December 28, 2017 | |
NCT02997501 | AstraZeneca|TigerMed | Lung Cancer | December 23, 2016 | Phase 3 |
NCT03784599 | The Netherlands Cancer Institute|AstraZeneca|Roche Pharma AG | Carcinoma, Non-Small-Cell Lung | December 18, 2018 | Phase 2 |
NCT04868877 | Merus N.V. | Non-Small Cell Lung Cancer Metastatic|Gastric Cancer|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma | April 28, 2021 | Phase 1|Phase 2 |
NCT05401110 | Karen Reckamp, MD, MS|Enviro Therapeutics, Inc.|Cedars-Sinai Medical Center | Non Small Cell Lung Cancer|Lung Cancer | December 14, 2023 | Phase 1 |
NCT02197247 | AstraZeneca | Non Small Cell Lung Cancer | December 4, 2014 | Phase 1 |
NCT05693090 | Kura Oncology, Inc. | NSCLC | February 1, 2023 | Phase 1 |
NCT04780568 | Ohio State University Comprehensive Cancer Center | Metastatic Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 | January 18, 2022 | Phase 1 |
NCT04486833 | Genprex, Inc. | Carcinoma, Non-Small Cell Lung | September 3, 2021 | Phase 1|Phase 2 |
NCT04811001 | Fondazione Ricerca Traslazionale | NSCLC | June 12, 2020 | Phase 2 |
NCT04487080 | Janssen Research & Development, LLC | Carcinoma, Non-Small-Cell Lung | September 30, 2020 | Phase 3 |
NCT02923947 | AstraZeneca|Quintiles, Inc. | Solid Tumours | May 4, 2017 | Phase 1 |
NCT05493501 | EQRx International, Inc. | NSCLC | December 14, 2022 | Phase 3 |
NCT03940703 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany|EMD Serono | Non-small Cell Lung Cancer | September 19, 2019 | Phase 2 |
NCT04410796 | Memorial Sloan Kettering Cancer Center|AstraZeneca|Guardant Health, Inc. | Metastatic Non-small Cell Lung Cancer | May 28, 2020 | Phase 2 |
NCT03586453 | Dana-Farber Cancer Institute|AstraZeneca | Carcinoma, Non-Small-Cell Lung | August 13, 2018 | Phase 2 |
NCT02520778 | National Cancer Institute (NCI) | Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Non-Small Cell Cancer AJCC v7|Stage IIIA Lung Non-Small Cell Cancer AJCC v7|Stage IIIB Lung Non-Small Cell Cancer AJCC v7|Stage IV Lung Non-Small Cell Cancer AJCC v7 | August 30, 2016 | Phase 1 |
NCT03219970 | AstraZeneca | Non-small Cell Lung Cancer | September 5, 2017 | |
NCT04425681 | Second Affiliated Hospital of Nanchang University|Nanchang University | Leptomeningeal Metastasis|Non-small Cell Lung Cancer|EGFR Activating Mutation | October 1, 2017 | Phase 2 |
NCT05526755 | AstraZeneca | Stage II-IIIB Non-small Cell Lung Carcinoma | March 6, 2023 | Phase 2 |
NCT05642572 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Recurrent Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8 | May 5, 2023 | Phase 2 |
NCT05017025 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Advanced Lung Non-Squamous Non-Small Cell Carcinoma|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 | February 17, 2022 | Phase 1|Phase 2 |
NCT02465060 | National Cancer Institute (NCI) | Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Multiple Myeloma|Ovarian Carcinoma|Pancreatic Carcinoma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Multiple Myeloma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Cancer|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Multiple Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer | August 12, 2015 | Phase 2 |
NCT04148898 | Second Affiliated Hospital of Nanchang University|Nanchang University | Leptomeningeal Metastasis|Non-small Cell Lung Cancer|EGFR Activating Mutation | November 1, 2019 | Phase 2 |
NCT02451852 | AstraZeneca | EGFR T790M Mutation Positive NSCLC | | |
NCT04029350 | Tianjin Medical University Cancer Institute and Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | July 31, 2019 | Phase 2 |
NCT03521154 | AstraZeneca | Non Small Cell Lung Cancer (Stage III) | July 19, 2018 | Phase 3 |
NCT05011487 | Sun Yat-sen University | Non-Small Cell Lung Cancer | August 13, 2021 | Phase 2 |
NCT03778229 | AstraZeneca|Hutchison MediPharma | Carcinoma | January 9, 2019 | Phase 2 |
NCT03769103 | British Columbia Cancer Agency|AstraZeneca|Princess Margaret Hospital, Canada|Sunnybrook Health Sciences Centre | Lung Cancer Non-small Cell Stage IV|Brain Metastases | March 19, 2019 | Phase 2 |
NCT04798638 | TYK Medicines, Inc | Healthy Volunteers | April 30, 2021 | Phase 1 |
NCT05489731 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. | Advanced Non-small Cell Lung Cancer | September 21, 2022 | Phase 1 |
NCT05458726 | Peking Union Medical College | EGFR T790M|Osimertinib|Non-small Cell Lung Cancer|ddPCR | September 15, 2020 | Phase 2 |
NCT02474355 | AstraZeneca|Parexel | Lung Cancer | September 18, 2015 | Phase 3 |
NCT02511106 | AstraZeneca | Stage IB-IIIA Non-small Cell Lung Carcinoma | October 21, 2015 | Phase 3 |
NCT05284994 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Nonsmall-cell Lung Cancer | March 11, 2022 | Phase 1|Phase 2 |
NCT02736513 | Soroka University Medical Center | Lung Cancer | May 2016 | Phase 2 |
NCT05801029 | AstraZeneca|Parexel | Non-Small Cell Lung Cancer (NSCLC) | July 18, 2023 | Phase 2 |
NCT02664935 | University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centres|Mirati Therapeutics Inc. | Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma | May 2015 | Phase 2 |
NCT03381274 | MedImmune LLC | Carcinoma, Non-Small-Cell Lung | May 8, 2018 | Phase 1|Phase 2 |
NCT02143466 | AstraZeneca | Advanced Non Small Cell Lung Cancer | August 5, 2014 | Phase 1 |
NCT05215951 | AstraZeneca | Lung Cancer | July 6, 2022 | Phase 2 |
NCT02759835 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Lung Adenocarcinoma|Lung Neoplasms | April 13, 2016 | Phase 2 |
NCT05089916 | AIO-Studien-gGmbH|AstraZeneca | NSCLC|EGFR Positive Non-small Cell Lung Cancer|Oligoprogression | January 20, 2022 | Phase 2 |
NCT02228369 | AstraZeneca | EGFR Mutation Positive Advanced Non Small Cell Lung Cancer | November 5, 2014 | Phase 1 |
NCT03853551 | AstraZeneca | Non Small Cell Lung Cancer (NSCLC) | April 18, 2019 | Phase 4 |
NCT03543683 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Non-Small Cell Lung Cancer Stage IIIB|Non-small Cell Lung Cancer Stage IV|EGFR T790M | August 1, 2020 | |
NCT05686434 | Tianjin Medical University Cancer Institute and Hospital | NSCLC, Stage I | October 14, 2022 | Phase 2 |
NCT02771314 | Hellenic Oncology Research Group | Non Small Cell Lung Cancer | August 2, 2016 | Phase 2 |
NCT04545710 | University of California, San Diego|Eli Lilly and Company | Lung Cancer | November 21, 2020 | Phase 2 |
NCT04862780 | Blueprint Medicines Corporation | Lung Neoplasms|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Neoplasms|Neoplasms by Site|Lung Diseases|Respiratory Tract Disease|Carcinoma, Bronchogenic|Bronchial Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Nerve Tissue|EGFR T790M|EGFR C797S|EGFR L858R|EGFR Gene Mutation|EGF-R Positive Non-Small Cell Lung Cancer|EGFR Exon 19 Deletion|EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance|EGFR Activating Mutation|Protein Kinase Inhibitors|Antineoplastic Agents|Thoracic Neoplasms | June 29, 2021 | Phase 1|Phase 2 |
NCT03790397 | Fundación GECP | Non Small Cell Lung Cancer | February 26, 2019 | |
NCT04179890 | Boehringer Ingelheim | Non-squamous, Non-Small Cell Lung Cancer | December 17, 2019 | |
NCT05163249 | Guangdong Association of Clinical Trials | Carcinoma, Non-Small-Cell Lung | December 2021 | Phase 2 |
NCT04769388 | Beijing Cancer Prevention & Treatment Society|Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non Small Cell Lung Cancer | December 28, 2021 | Phase 2 |
NCT02224053 | AstraZeneca | Healthy Volunteer | September 2014 | Phase 1 |
NCT02803203 | Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. | Non-small Cell Lung Cancer|EGFR-mutant Lung Cancers | June 29, 2016 | Phase 1|Phase 2 |
NCT04085315 | Collin Blakely|Puma Biotechnology, Inc.|University of California, San Francisco | Lung Cancer Metastatic|EGFR Gene Mutation | November 12, 2019 | Phase 1 |
NCT04765059 | AstraZeneca|Parexel | Non-small Cell Lung Cancer | September 12, 2021 | Phase 3 |
NCT03392246 | Dana-Farber Cancer Institute|National Comprehensive Cancer Network | Non-small Cell Lung Cancer | January 31, 2018 | Phase 2 |
NCT05020769 | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | January 6, 2022 | Phase 2|Phase 3 |
NCT04335292 | Mark Vincent|AstraZeneca|Lawson Health Research Institute | Non-Small Cell Lung Cancer | January 6, 2021 | Phase 2 |
NCT02769286 | Chonnam National University Hospital | Lung Neoplasms|EGFR Gene Mutations | August 2016 | Phase 2 |
NCT03257124 | Samsung Medical Center | Non-Small Cell Lung Cancer With EGFR T790M Mutation|With Brain and+or Leptomeningeal Metastasis|Failed Tyrosine Kinase Inhibitors | May 8, 2017 | Phase 2 |
NCT03891615 | Massachusetts General Hospital|Tesaro, Inc. | Lung Cancer | June 6, 2019 | Phase 1 |
NCT03433469 | University of California, San Francisco|AstraZeneca | Stage I Non-Small Cell Lung Cancer|Stage IA Non-Small Cell Lung Cancer|Stage IB Non-Small Cell Lung Cancer|Stage II Non-Small Cell Lung Cancer|Stage IIA Non-Small Cell Lung Cancer|Stage IIB Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer | July 31, 2018 | Phase 2 |
NCT04285671 | Jonsson Comprehensive Cancer Center|Eli Lilly and Company|Genentech, Inc. | Metastatic Lung Non-Small Cell Carcinoma|Refractory Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 | January 29, 2021 | Phase 1|Phase 2 |
NCT04965701 | Istituto Oncologico Veneto IRCCS | EGF-R Positive Non-Small Cell Lung Cancer | June 1, 2018 | |
NCT03434418 | Duke University | Non Small Cell Lung Cancer | June 30, 2018 | Phase 2 |
NCT05261399 | AstraZeneca | Carcinoma|Non-Small-Cell Lung | August 3, 2022 | Phase 3 |
NCT02161770 | AstraZeneca | Solid Tumours | December 22, 2014 | Phase 1 |
NCT03255083 | Daiichi Sankyo, Inc. | Non-small Cell Lung Cancer (NSCLC) | April 10, 2019 | Phase 1 |
NCT04772235 | Instituto Oncológico Dr Rosell|Turning Point Therapeutics, Inc. | Nsclc | February 11, 2022 | Phase 1 |
NCT05948813 | TYK Medicines, Inc | NSCLC|EGFR Activating Mutation|Brain Metastases | July 30, 2023 | Phase 2 |
NCT03497767 | Trans Tasman Radiation Oncology Group | Metastatic Non Small Cell Lung Cancer | August 15, 2019 | Phase 2 |
NCT03410043 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|National Comprehensive Cancer Network | Lung Non-Small Cell Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 | January 17, 2018 | Phase 2 |
NCT02442349 | AstraZeneca | Non-Small Cell Lung Cancer | June 22, 2015 | Phase 2 |
NCT01951599 | AstraZeneca | Healthy Volunteers | October 9, 2013 | Phase 1 |
NCT03755102 | Memorial Sloan Kettering Cancer Center | EGFR Gene Mutation|Lung Cancer|Lung Cancer Metastatic | November 21, 2018 | Early Phase 1 |
NCT03463525 | AstraZeneca | Non-small Cell Lung Cancer | October 24, 2018 | Phase 1 |
NCT05153408 | Blueprint Medicines Corporation | Lung Neoplasm|Carcinoma, Non-Small-Cell Lung|Respiratory Tract Neoplasms|Neoplasms|Neoplasms by Site|Lung Diseases|Respiratory Tract Diseases|Carcinoma, Bronchogenic|Bronchial Neoplasms|Adenocarcinoma|Carcinoma|Neoplasms by Histologic Type|Neoplasms, Nerve Tissue|EGFR C797S|EGFR C797A|EGFR L858R|EGFR Exon 19 Deletion|EGFR Gene Mutation|EGF-R Positive Non-Small Cell Lung Cancer|EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance|EGFR Activating Mutation|Thoracic Neoplasms|Antineoplastic Agents|Protein Kinase Inhibitors|EGFR C797G|EGFR C797X|Non Small Cell Lung Cancer | January 13, 2022 | Phase 1 |
NCT04035486 | AstraZeneca | Non-Small Cell Lung Cancer | July 2, 2019 | Phase 3 |
NCT04721015 | AbbVie | Advanced Solid Tumors Cancer|Non Small Cell Lung Cancer (NSCLC) | February 23, 2021 | Phase 1 |
NCT02491944 | AstraZeneca | Oncology | July 2015 | Phase 1 |
NCT04762199 | Emory University|National Cancer Institute (NCI) | Advanced Lung Non-Small Cell Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 | February 24, 2021 | Phase 1 |
NCT02151981 | AstraZeneca | Anticancer Treatment | August 4, 2014 | Phase 3 |